Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SpingWorks

- PMLiVE

Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ hopes to catch up to rivals using the French biotech's candidate

- PMLiVE

Acceleron scraps rare muscular dystrophy drug

Clinical profile not strong enough to push into late-stage testing

- PMLiVE

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

Could acquire up to 11 Roivant spinouts

- PMLiVE

Pfizer goes big on gene therapy with $500m facility spend

Continues to build on its growing gene therapy business

- PMLiVE

Sarepta investigating mistakenly submitted Duchenne therapy report

Study participant fell seriously ill

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

- PMLiVE

Pfizer set to unveil Mylan merger and spin-off

Follows consumer health deal with GSK

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links